title: Amantadine in the akinetic-rigid variant of Huntington's disease.
abstract: OBJECTIVE
  To report the effects of amantadine on an akinetic-rigid variant of Huntington's disease (HD).
  
  
  METHODS
  We describe a 36-year-old woman with HD who was treated with intravenous amantadine for 5 days. The woman was evaluated with the Unified Huntington's Disease Rating Scale before and after treatment. Parkinsonism, bradykinesia, and dystonia improved significantly.
  
  
  CONCLUSIONS
  Amantadine is a noncompetitive N-methyl d-aspartate receptor antagonist. It is mainly used in the treatment of Parkinson's disease, as it increases dopamine levels in the brain. This effect is said to ameliorate akinesia. Although the effect of amantadine on choreatic dystonia in HD has been reported in several studies, to the best of our knowledge, this is the first report of the ameliorative effects of amantadine on the rigid form of HD. Our patient showed improvements of gait, parkinsonism, and dystonia. Fine-motor tasks and eye movement did not change significantly.
  
  
  CONCLUSIONS
  We suggest that amantadine treatment might be of value to patients with the akinetic-rigid variant of HD.
authors.affiliation: Karl-Franzens University Graz, Graz, Austria.
authors.forename: Markus K
authors.initials: MK
authors.lastname: Magnet
authors.forename: Raphael M
authors.initials: RM
authors.lastname: Bonelli
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Kapfhammer
mesh_terms: D000328:Adult; D000547:Amantadine / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D000547:Amantadine